The purpose of this program is to prevent and reduce the high burden of cervical cancer in Haiti through increased access to human papillomavirus (HPV) vaccination. The specific objectives include:
- Demonstrating feasibility and acceptance of HPV vaccination in select regions of Haiti.
- Enabling local organizations and institutions in Haiti to gain operational experience in designing and implementing HPV vaccination projects
To achieve this, Merck has joined with the local partner, Zanmi Lasante, a well-known and highly regarded entity by the Haitian Ministry of Health and the local population. Merck’s main activity in supporting this program involves the donation of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]. The HPV Types 16 and 18 account for more than 60% of diagnosed cases in Haiti according to 2012 data (1). Zanmi Lasante is responsible for planning and executing the program activities with Merck’s support. Activities include education campaigns to raise awareness about cervical cancer, HPV and the HPV vaccine in rural and urban towns alike. These are conducted in partnership with local community leaders, schools, educators and local health teams.
(1) WHO/ICO Information Center on HPV and Cervical Cancer.